Injection-site granulomas resulting from the administration of both leuprorelin acetate and goserelin acetate for the treatment of prostatic cancer.
Although injection-site granulomas caused by leuprorelin acetate have been reported, there have been no reports of granulomas caused by both leuprorelin acetate and goserelin acetate. An 81-year-old man presented with subcutaneous nodules of the abdominal wall and upper arm, where 11.25 mg of leuprorelin acetate had been injected for the treatment of prostate cancer. Because of these nodules, treatment was changed to goserelin acetate. Nevertheless, he presented with another subcutaneous nodule at the injection site. Histological examination showed that these nodules consisted of numerous giant cells that were CD3-positive T lymphocytes and CD68-positive histiocytes associated with granulomatous changes. The granulomas had likely been caused by delayed-type hypersensitivity to leuprorelin acetate injection. The granuloma that formed after goserelin acetate injection might thus have developed owing to the immunogenicity of the previous leuprorelin acetate injections. The patient underwent surgical castration. The present case suggests that both leuprorelin acetate and goserelin acetate can cause injection-site disorders.
Shiota
Masaki
M
Department of Urology and Pathology, Saga Prefectural Hospital, Koseikan, Saga, Japan. shiota1976@yahoo.co.jp
Tokuda
Noriaki
N
Kanou
Takehiro
T
Yamasaki
Humio
H
D000369:Aged, 80 and over; D017273:Goserelin / Q000008:administration & dosage / Q000009:adverse effects*; D006099:Granuloma / Q000139:chemically induced*; D006801:Humans; D007267:Injections; D016729:Leuprolide / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D017273:Goserelin; D016729:Leuprolide